PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer

Clinical trial NCT05310305 · UNKNOWN

Trial details

NCT number: NCT05310305
Sponsor: Lei Li
Status: UNKNOWN
Study type: OBSERVATIONAL

Immune Checkpoint Inhibitors Anti-programmed Death-1 Antibody Radiotherapy Recurrent Cervical Carcinoma Metastatic Cervical Carcinoma Persistent Advanced Cervical Carcinoma Objective Remission Rate Progression-free Survival Overall Survival Severe Adverse Events

Start date: 2022-03-26
Primary completion: 2022-09-26
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.